Osteonecrosis of the jaw: new developments in an old disease.
Khan
Aliya
A
D019386:Alendronate / Q000009:adverse effects; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D012968:Etidronic Acid / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000473:pathology; D010020:Osteonecrosis / Q000139:chemically induced* / Q000473:pathology; D000068296:Risedronic Acid; D012307:Risk Factors
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate